Company Performance - Day One Biopharmaceuticals reported a quarterly loss of $0.35 per share, better than the Zacks Consensus Estimate of a loss of $0.46, and an improvement from a loss of $0.72 per share a year ago, representing an earnings surprise of 23.91% [1] - The company posted revenues of $30.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.90%, compared to zero revenues a year ago [2] - The stock has lost about 41% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.44 on revenues of $34.88 million, and for the current fiscal year, it is -$1.67 on revenues of $149.97 million [7] - The estimate revisions trend for Day One Biopharmaceuticals is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Day One Biopharmaceuticals belongs, is currently in the top 31% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Jazz, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $897.84 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.52%. This compares to year-ago revenues of $901.98 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commen ...

Group 1 - Arcutis Biotherapeutics reported a quarterly loss of $0.20 per share, which was better than the Zacks Consensus Estimate of a loss of $0.21, and an improvement from a loss of $0.32 per share a year ago, resulting in an earnings surprise of 4.76% [1] - The company achieved revenues of $65.85 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26%, and showing a year-over-year increase from $49.57 million [2] - Over the last four quarters, Arcutis Biotherapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2 - The stock has increased approximately 10.6% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $72.93 million, and for the current fiscal year, it is -$0.55 on revenues of $307.74 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis Biotherapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Company Performance - Ultragenyx reported a quarterly loss of $1.57 per share, slightly worse than the Zacks Consensus Estimate of a loss of $1.54, but an improvement from a loss of $2.03 per share a year ago, indicating a year-over-year improvement in loss figures [1] - The company posted revenues of $139.29 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.90%, but showing an increase from $108.83 million in the same quarter last year [2] - Over the last four quarters, Ultragenyx has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Ultragenyx shares have declined approximately 7.6% since the beginning of the year, compared to a decline of 3.9% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.27 on revenues of $160.05 million, and for the current fiscal year, it is -$5.14 on revenues of $653.73 million [7] - The estimate revisions trend for Ultragenyx is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Ultragenyx belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ultragenyx's stock performance [5]

分组1 - Voyager Therapeutics reported a quarterly loss of $0.53 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and compared to a loss of $0.20 per share a year ago, indicating an earnings surprise of -51.43% [1] - The company posted revenues of $6.47 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 66.26%, and down from $19.52 million in the same quarter last year [2] - Voyager Therapeutics shares have declined approximately 38.5% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.31 on revenues of $19.19 million, and for the current fiscal year, it is -$1.41 on revenues of $90.91 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Overview - Ovid Therapeutics (OVID) is expected to report a quarterly loss of $0.14 per share, reflecting a year-over-year change of +17.7% [3] - Revenues are anticipated to be $0.07 million, down 53.3% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Most Accurate Estimate for Ovid is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.45%, suggesting a bearish sentiment among analysts [10] Historical Performance - In the last reported quarter, Ovid was expected to post a loss of $0.16 per share but actually reported a loss of $0.13, achieving a surprise of +18.75% [12] - Over the past four quarters, Ovid has beaten consensus EPS estimates three times [13] Comparative Industry Analysis - ImmunityBio (IBRX), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.12 for the same quarter, indicating a year-over-year change of +40% [17] - ImmunityBio's revenues are projected to be $15.69 million, up 39125% from the previous year [17] - The consensus EPS estimate for ImmunityBio has been revised 1.5% lower over the last 30 days, resulting in an Earnings ESP of -2.85% [18]

Company Performance - Aligos Therapeutics reported a quarterly loss of $2.11 per share, which was better than the Zacks Consensus Estimate of a loss of $2.80, and an improvement from a loss of $5.50 per share a year ago, indicating a 24.64% earnings surprise [1] - The company posted revenues of $0.31 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 68.90%, and down from $0.99 million in the same quarter last year [2] - Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Aligos Therapeutics shares have declined approximately 87.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.74 on $1 million in revenues, and for the current fiscal year, it is -$8.66 on $39.5 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Aligos Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos Therapeutics' stock performance [5][6]

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.04%. A quarter ago, it was expected that this company would post earnings of $1.29 per share when it actually produced earnings of $1.52, delivering a surprise of 17.83%.Over the last four quarters, the c ...

Financial Performance - CorMedix reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, compared to a loss of $0.25 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $39.08 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.76%, compared to zero revenues a year ago [2] Stock Performance - CorMedix shares have increased approximately 11.5% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $26.31 million, and for the current fiscal year, it is $0.72 on revenues of $132.38 million [7] - The estimate revisions trend for CorMedix is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which CorMedix belongs, is currently in the top 31% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.71%. A quarter ago, it was expected that this company would post a loss of $1.10 per share when it actually produced a loss of $1.09, delivering a surprise of 0.91%.Over the last four quarters, the company has s ...